Literature DB >> 7724606

Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein.

S Haraguchi1, R A Good, M James-Yarish, G J Cianciolo, N K Day.   

Abstract

The influence of a synthetic retroviral peptide, CKS-17, on T helper type 1 (Th1)- or Th2-related cytokines was investigated in human blood mononuclear cells. Cells were stimulated with staphylococcal enterotoxin A, anti-CD3 plus anti-CD28 monoclonal antibodies, or lipopolysaccharide to induce cytokine mRNA. mRNA was detected by a reverse transcription-polymerase chain reaction or Northern blot analysis. CKS-17 down-regulated stimulant-induced mRNA accumulation for interferon gamma (IFN-gamma), interleukin (IL)-2, and p40 heavy and p35 light chains of IL-12, a cytokine that mediates development of Th1 response. CKS-17 up-regulated stimulant-induced mRNA accumulation of IL-10 and did not suppress Th2-related cytokine (IL-4, IL-5, IL-6, or IL-13) mRNA expression. A reverse sequence of CKS-17 peptide, used as a control, showed no such action. Anti-human IL-10 monoclonal antibody blocked ability of CKS-17 to inhibit mRNA accumulation for IFN-gamma but not the CKS-17 suppressive activity of IL-12 p40 heavy chain mRNA. Thus, CKS-17-mediated suppression of IFN-gamma mRNA expression is dependent upon augmentation of IL-10 production by CKS-17. This conserved component of several retroviral envelope proteins, CKS-17, may act as an immunomodulatory epitope responsible for cytokine dysregulation that leads to suppression of cellular immunity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7724606      PMCID: PMC42217          DOI: 10.1073/pnas.92.8.3611

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  REDUCED ANTIBODY FORMING CAPACITY DURING THE INCUBATION PERIOD OF PASSAGE A LEUKEMIA IN C3H MICE.

Authors:  R D PETERSON; R HENDRICKSON; R A GOOD
Journal:  Proc Soc Exp Biol Med       Date:  1963-11

2.  Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses.

Authors:  G J Cianciolo; T J Matthews; D P Bolognesi; R Snyderman
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

3.  Suppression of gamma interferon production by inactivated feline leukemia virus.

Authors:  R W Engelman; R W Fulton; R A Good; N K Day
Journal:  Science       Date:  1985-03-15       Impact factor: 47.728

4.  Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins.

Authors:  G J Cianciolo; T D Copeland; S Oroszlan; R Snyderman
Journal:  Science       Date:  1985-10-25       Impact factor: 47.728

5.  Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukemia virus.

Authors:  L E Mathes; R G Olsen; L C Hebebrand; E A Hoover; J P Schaller; P W Adams; W S Nichols
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

6.  Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus.

Authors:  P Sonigo; C Barker; E Hunter; S Wain-Hobson
Journal:  Cell       Date:  1986-05-09       Impact factor: 41.582

Review 7.  Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency.

Authors:  J Chehimi; G Trinchieri
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

Review 8.  Properties and functions of interleukin-10.

Authors:  T R Mosmann
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

9.  Similarity between p15E of murine and feline leukaemia viruses and p21 of HTLV.

Authors:  G J Cianciolo; R J Kipnis; R Snyderman
Journal:  Nature       Date:  1984 Oct 11-17       Impact factor: 49.962

10.  Retrovirus-mediated immunosuppression. II. FeLV-UV alters in vitro murine T lymphocyte behavior by reversibly impairing lymphokine secretion.

Authors:  C G Orosz; N E Zinn; R G Olsen; L E Mathes
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

View more
  23 in total

Review 1.  Sympathetic modulation of immunity: relevance to disease.

Authors:  Denise L Bellinger; Brooke A Millar; Sam Perez; Jeff Carter; Carlo Wood; Srinivasan ThyagaRajan; Christine Molinaro; Cheri Lubahn; Dianne Lorton
Journal:  Cell Immunol       Date:  2008-03-04       Impact factor: 4.868

2.  HIV-1 envelope gp41 is a potent inhibitor of chemoattractant receptor expression and function in monocytes.

Authors:  H Ueda; O M Howard; M C Grimm; S B Su; W Gong; G Evans; F W Ruscetti; J J Oppenheim; J M Wang
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

3.  Antibody to human endogenous retrovirus peptide in urine of human immunodeficiency virus type 1-positive patients.

Authors:  R W Stevens; A L Baltch; R P Smith; B J McCreedy; P B Michelsen; L H Bopp; H B Urnovitz
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

4.  Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101.

Authors:  B Kitze; K Usuku; Y Yamano; S Yashiki; M Nakamura; T Fujiyoshi; S Izumo; M Osame; S Sonoda
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

5.  Induction of intracellular cAMP by a synthetic retroviral envelope peptide: a possible mechanism of immunopathogenesis in retroviral infections.

Authors:  S Haraguchi; R A Good; M James-Yarish; G J Cianciolo; N K Day
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

6.  Increased interleukin-10 mRNA expression in tumor-bearing or persistently lymphocytotic animals infected with bovine leukemia virus.

Authors:  D Pyeon; K L O'Reilly; G A Splitter
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Lack of immunotoxicity of saquinavir (Ro 31-8959) used alone or in double or triple combination with AZT and ddC.

Authors:  M Viora; G Di Genova; M G Quaranta; M Boirivant; B Camponeschi
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

8.  Tumor cells expressing a retroviral envelope escape immune rejection in vivo.

Authors:  M Mangeney; T Heidmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

Review 9.  A potent immunosuppressive retroviral peptide: cytokine patterns and signaling pathways.

Authors:  Soichi Haraguchi; Robert A Good; Noorbibi K Day-Good
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

10.  Cytotoxic necrotizing factor 1 enhances reactive oxygen species-dependent transcription and secretion of proinflammatory cytokines in human uroepithelial cells.

Authors:  Loredana Falzano; Maria Giovanna Quaranta; Sara Travaglione; Perla Filippini; Alessia Fabbri; Marina Viora; Gianfranco Donelli; Carla Fiorentini
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.